Flush with cash, com­pu­ta­tion­al chem­istry pi­o­neer Nim­bus con­sid­ers next steps. Is an IPO in the fu­ture?

When Bruce Booth helped launch Nim­bus Ther­a­peu­tics back in 2009, it was dif­fi­cult to find co-in­vestors will­ing to back the com­pa­ny’s pi­o­neer­ing com­pu­ta­tion­al chem­istry plat­form. Those were the “lean­er times for the sec­tor,” he said, and the bud­get was tight.

That all end­ed when Gilead inked a mas­sive $1.2 bil­lion NASH deal with Nim­bus in 2016. And the cash keeps flow­ing for the Cam­bridge, MA-based biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER